Lutetium Lu 177 Vipivotide Tetraxetan
Pluvicto is a targeted radioligand therapy used to treat adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer that has progressed despite other treatments. The medication delivers radioactive material directly to cancer cells expressing PSMA, allowing targeted radiation to destroy them while minimizing exposure to surrounding healthy tissue. It is administered as an intravenous infusion, typically every 6 weeks for up to 6 doses.
Pluvicto is a PSMA-targeted radiopharmaceutical used to treat advanced prostate cancer by delivering radioactive treatment directly to cancer cells.
Key facts at a glance
- RxNorm
- 2597047
- Generic
- Pluvicto
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Pluvicto is indicated for the treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) that has progressed following treatment with other anticancer therapies, including androgen receptor pathway inhibitors and taxane-based chemotherapy.
Pluvicto is a radioligand therapy that consists of a radioactive isotope (lutetium-177) linked to a molecule that binds to PSMA, a protein highly expressed on prostate cancer cells. Once bound, the radioactive emission damages and destroys the cancer cells from within.
Pluvicto carries risks including bone marrow suppression, kidney toxicity, and radiation exposure to others. It should only be administered by qualified healthcare professionals in approved facilities with appropriate radiation safety measures. Patients should follow specific precautions regarding bodily fluid exposure for up to a week after each dose. Regular blood tests are required to monitor blood cell counts and organ function during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy